Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome.

Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-6362 (Electronic) Linking ISSN: 14786354 NLM ISO Abbreviation: Arthritis Res Ther Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Epistasis, Genetic/*genetics ; HLA-DR3 Antigen/*genetics ; Receptors, Purinergic P2X7/*genetics ; Sjogren's Syndrome/*genetics; Antibodies, Antinuclear/blood ; Autoantibodies/blood ; Autoantigens/immunology ; Enzyme-Linked Immunosorbent Assay ; Female ; Genotype ; Humans ; Interleukin-18/blood ; Male ; Polymorphism, Single Nucleotide ; Ribonucleoproteins/immunology ; Sjogren's Syndrome/blood ; Sjogren's Syndrome/immunology ; SS-B Antigen

Introduction: The aim of this study was to examine the association between functional polymorphisms in the pro-inflammatory P2X7 receptor and the Ro/La autoantibody response in primary Sjögren's syndrome (pSS).
Methods: Twelve functional P2RX7 polymorphisms were genotyped in 114 pSS patients fulfilling the Revised American-European Consensus Criteria for pSS, and 136 controls. Genotyping of the A1405G (rs2230912) polymorphism was performed on a replication cohort consisting of 281 pSS patients and 534 controls. P2X7 receptor function in lymphocytes and monocytes was assessed by measurement of ATP-induced ethidium+ uptake. Serum IL-18 levels were determined by ELISA.
Results: The minor allele of P2RX7 A1405G is a tag for a common haplotype associated with gain in receptor function, as assessed by ATP-induced ethidium+ uptake. A positive association between 1405G and anti-Ro±La seropositive pSS patients was observed in Cohort 1. Although not replicated in Cohort 2, there was a consistent, significant, negative epistatic interaction effect with HLA-DR3 in seropositive pSS patients from both cohorts, thereby implicating this gain of function variant in the pathogenesis of pSS. Serum IL-18 was elevated in seropositive pSS patients, but was not influenced by P2RX7 A1405G.
Conclusions: The P2RX7 1405G gain-of-function haplotype may be a risk factor for seropositive pSS in a subset of subjects who do not carry HLA risk alleles, but has no effect in subjects who do (epistasis). Potential mechanisms relate to autoantigen exposure and inflammatory cytokine expression. The observed elevation of IL-18 levels is consistent with P2X7 receptor activation in seropositive pSS patients. Collectively these findings implicate P2X7 receptor function in the pathogenesis of pSS.

Scand J Immunol. 2004 Jun;59(6):592-9. (PMID: 15182255)
Purinergic Signal. 2009 Jun;5(2):257-62. (PMID: 19319666)
PLoS One. 2011;6(12):e28727. (PMID: 22174879)
Cell Immunol. 2012 Mar-Apr;276(1-2):168-75. (PMID: 22703695)
J Immunol. 2002 Jun 15;168(12):6436-45. (PMID: 12055263)
EMBO J. 2001 Nov 15;20(22):6347-58. (PMID: 11707406)
Am J Physiol Cell Physiol. 2009 Aug;297(2):C430-9. (PMID: 19494237)
Tissue Antigens. 2008 Nov;72(5):487-90. (PMID: 18937793)
Curr Opin Immunol. 2005 Dec;17(6):583-8. (PMID: 16214321)
Crit Rev Immunol. 2006;26(6):499-513. (PMID: 17341191)
Acta Physiol (Oxf). 2011 Jul;202(3):501-22. (PMID: 21073662)
Clin Immunol Immunopathol. 1996 Jun;79(3):314-8. (PMID: 8635291)
Clin Chem. 2006 Jun;52(6):995-1004. (PMID: 16613995)
Clin Exp Immunol. 1998 Feb;111(2):365-71. (PMID: 9486405)
Nat Clin Pract Rheumatol. 2006 May;2(5):262-9. (PMID: 16932699)
J Immunol. 2004 Mar 15;172(6):3399-405. (PMID: 15004138)
Cell Signal. 2003 Jan;15(1):103-13. (PMID: 12401525)
J Immunol. 2008 Jan 1;180(1):300-8. (PMID: 18097031)
Autoimmun Rev. 2012 Feb;11(4):281-7. (PMID: 22001416)
J Biol Chem. 1998 Nov 13;273(46):30208-17. (PMID: 9804778)
J Leukoc Biol. 2004 Jun;75(6):1173-82. (PMID: 15075366)
J Immunol. 2000 Oct 15;165(8):4615-23. (PMID: 11035104)
Arthritis Res Ther. 2008;10(2):R31. (PMID: 18328102)
J Immunol Methods. 2007 Aug 31;325(1-2):67-77. (PMID: 17618646)
Am J Hum Genet. 2001 Apr;68(4):978-89. (PMID: 11254454)
Immunol Cell Biol. 2009 Jan;87(1):81-90. (PMID: 18936772)
Hum Immunol. 2010 Aug;71(8):818-25. (PMID: 20493226)
Nature. 2006 Mar 9;440(7081):228-32. (PMID: 16407890)
Trends Pharmacol Sci. 2007 Sep;28(9):465-72. (PMID: 17692395)
PLoS One. 2010 Oct 26;5(10):e13454. (PMID: 21049023)
Ann Rheum Dis. 2008 Jun;67(6):849-54. (PMID: 17878210)
Nature. 2006 Aug 3;442(7102):527-32. (PMID: 16885977)
J Immunol. 1997 Aug 1;159(3):1451-8. (PMID: 9233643)
J Immunol. 2011 Sep 1;187(5):2365-75. (PMID: 21821797)
J Biol Chem. 2009 Feb 20;284(8):4815-22. (PMID: 19097994)
Ann Rheum Dis. 2008 Oct;67(10):1382-9. (PMID: 17921182)
Inflammation. 2008 Apr;31(2):84-90. (PMID: 18040764)
J Clin Rheumatol. 2012 Sep;18(6):290-3. (PMID: 22955477)
Arthritis Res Ther. 2004;6(5):R447-56. (PMID: 15380044)
J Inflamm (Lond). 2007 Mar 16;4:5. (PMID: 17367517)
Arthritis Res Ther. 2005;7(3):R468-75. (PMID: 15899033)
Annu Rev Immunol. 2009;27:621-68. (PMID: 19302049)
Ann Rheum Dis. 2002 Jun;61(6):554-8. (PMID: 12006334)
J Immunol. 2006 Feb 15;176(4):2152-60. (PMID: 16455971)
Trends Neurosci. 2009 May;32(5):241-8. (PMID: 19359051)
Nat Genet. 2006 Aug;38(8):904-9. (PMID: 16862161)
J Dent Res. 2009 Oct;88(10):927-32. (PMID: 19783801)
FASEB J. 2010 Aug;24(8):2916-27. (PMID: 20360457)
Autoimmun Rev. 2002 Feb;1(1-2):29-35. (PMID: 12849055)
J Immunol. 2008 Aug 15;181(4):2898-906. (PMID: 18684981)
Genes Immun. 2004 Nov;5(7):588-91. (PMID: 15306849)
Nat Clin Pract Rheumatol. 2006 Jun;2(6):330-7. (PMID: 16932712)
Korean J Physiol Pharmacol. 2009 Jun;13(3):175-9. (PMID: 19885034)

P50 AR060804 United States AR NIAMS NIH HHS

0 (Antibodies, Antinuclear)
0 (Autoantibodies)
0 (Autoantigens)
0 (HLA-DR3 Antigen)
0 (Interleukin-18)
0 (Receptors, Purinergic P2X7)
0 (Ribonucleoproteins)
0 (SS-A antibodies)
0 (SS-A antigen)

Date Created: 20130704 Date Completed: 20150910 Latest Revision: 20231213

20231215

PMC3979150

10.1186/ar4248

23819992